Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Grassley Targets FDA's Handling Of Adderall XR Adverse Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Finance Committee chairman expresses concern that agency may have sought to dissuade Health Canada from suspending Adderall XR sales because "FDA could not handle another 'drug safety crisis.'" Grassley requests records of FDA's meetings with Health Canada.
Advertisement

Related Content

FDA's Graham To Present Overview At COX-2 Advisory Committee Meeting
Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"
Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"
FDA Office Of Drug Safety “Separate But Unequal” To Office Of New Drugs, Senate Inquiry Finds

Topics

Advertisement
UsernamePublicRestriction

Register

PS061558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel